Update: Profound Medical’s Scheduled Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Moved Up to 9:00am PT on January 16th
13 janv. 2025 08h00 HE
|
Profound Medical Corp.
TORONTO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues
08 janv. 2025 07h30 HE
|
Profound Medical Corp.
– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound...
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 08h15 HE
|
Profound Medical Corp.
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares
10 déc. 2024 09h55 HE
|
Profound Medical Corp.
TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public...
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares
06 déc. 2024 09h04 HE
|
Profound Medical Corp.
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical...
Profound Medical Announces Proposed Public Offering of Common Shares
05 déc. 2024 16h48 HE
|
Profound Medical Corp.
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp....
Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy
02 déc. 2024 07h30 HE
|
Profound Medical Corp.
– Combines Profound’s TULSA-PRO® and Siemens Healthineers’ Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurate and precise diagnosis, treatment, and follow-up – ...
Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’
26 nov. 2024 07h45 HE
|
Profound Medical Corp.
TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical to Participate in the Stifel 2024 Healthcare Conference
12 nov. 2024 08h00 HE
|
Profound Medical Corp.
TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces Third Quarter 2024 Financial Results
07 nov. 2024 16h05 HE
|
Profound Medical Corp.
TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...